| Natural variation in Fc glycosylation of HIV-specific antibodies impacts antiviral activity ME Ackerman, M Crispin, X Yu, K Baruah, AW Boesch, DJ Harvey, ... The Journal of clinical investigation 123 (5), 2183-2192, 2013 | 380 | 2013 |
| Impact of immune complex size and glycosylation on IgG binding to human FcγRs A Lux, X Yu, CN Scanlan, F Nimmerjahn The Journal of Immunology 190 (8), 4315-4323, 2013 | 295 | 2013 |
| Dissecting the molecular mechanism of IVIg therapy: the interaction between serum IgG and DC-SIGN is independent of antibody glycoform or Fc domain X Yu, S Vasiljevic, DA Mitchell, M Crispin, CN Scanlan Journal of molecular biology 425 (8), 1253-1258, 2013 | 138 | 2013 |
| Identification of antibody glycosylation structures that predict monoclonal antibody Fc-effector function AW Chung, M Crispin, L Pritchard, H Robinson, MK Gorny, X Yu, ... AIDS (London, England) 28 (17), 2523, 2014 | 121 | 2014 |
| Engineering hydrophobic protein–carbohydrate interactions to fine-tune monoclonal antibodies X Yu, K Baruah, DJ Harvey, S Vasiljevic, DS Alonzi, BD Song, MK Higgins, ... Journal of the American Chemical Society 135 (26), 9723-9732, 2013 | 103 | 2013 |
| Crystal structure of sialylated IgG Fc: implications for the mechanism of intravenous immunoglobulin therapy M Crispin, X Yu, TA Bowden Proceedings of the National Academy of Sciences 110 (38), E3544-E3546, 2013 | 101 | 2013 |
| Complex interplay between epitope specificity and isotype dictates the biological activity of anti-human CD40 antibodies X Yu, HTC Chan, CM Orr, O Dadas, SG Booth, LN Dahal, CA Penfold, ... Cancer cell 33 (4), 664-675. e4, 2018 | 97 | 2018 |
| Chemical and structural analysis of an antibody folding intermediate trapped during glycan biosynthesis TA Bowden, K Baruah, CH Coles, DJ Harvey, X Yu, BD Song, DI Stuart, ... Journal of the American Chemical Society 134 (42), 17554-17563, 2012 | 87 | 2012 |
| Improving antibody-based cancer therapeutics through glycan engineering X Yu, MJE Marshall, MS Cragg, M Crispin BioDrugs 31, 151-166, 2017 | 64 | 2017 |
| Isotype switching converts anti-CD40 antagonism to agonism to elicit potent antitumor activity X Yu, HTC Chan, H Fisher, CA Penfold, J Kim, T Inzhelevskaya, ... Cancer Cell 37 (6), 850-866. e7, 2020 | 51 | 2020 |
| Reducing affinity as a strategy to boost immunomodulatory antibody agonism X Yu, CM Orr, HTC Chan, S James, CA Penfold, J Kim, T Inzhelevskaya, ... Nature 614 (7948), 539-547, 2023 | 47 | 2023 |
| Targeting FcγRs to treat antibody-dependent autoimmunity X Yu, AH Lazarus Autoimmunity reviews 15 (6), 510-512, 2016 | 38 | 2016 |
| TNF receptor agonists induce distinct receptor clusters to mediate differential agonistic activity X Yu, S James, JH Felce, B Kellermayer, DA Johnston, HTC Chan, ... Communications Biology 4 (1), 772, 2021 | 29 | 2021 |
| Fragments of bacterial endoglycosidase s and immunoglobulin g reveal subdomains of each that contribute to deglycosylation EV Dixon, JK Claridge, DJ Harvey, K Baruah, X Yu, S Vesiljevic, S Mattick, ... Journal of Biological Chemistry 289 (20), 13876-13889, 2014 | 28 | 2014 |
| Monovalent Fc receptor blockade by an anti–Fcγ receptor/albumin fusion protein ameliorates murine ITP with abrogated toxicity X Yu, M Menard, J Prechl, V Bhakta, WP Sheffield, AH Lazarus Blood, The Journal of the American Society of Hematology 127 (1), 132-138, 2016 | 25 | 2016 |
| Hinge disulfides in human IgG2 CD40 antibodies modulate receptor signaling by regulation of conformation and flexibility CM Orr, H Fisher, X Yu, CHT Chan, Y Gao, PJ Duriez, SG Booth, I Elliott, ... Science Immunology 7 (73), eabm3723, 2022 | 24 | 2022 |
| A monoclonal antibody with anti‐D–like activity in murine immune thrombocytopenia requires Fc domain function for immune thrombocytopenia ameliorative effects X Yu, M Menard, G Seabright, M Crispin, AH Lazarus Transfusion 55 (6pt2), 1501-1511, 2015 | 17 | 2015 |
| Profiling of donor-specific immune effector signatures in response to rituximab in a human whole blood loop assay using blood from CLL patients M Eltahir, E Fletcher, L Dynesius, JL Jarblad, M Lord, I Laurén, M Zekarias, ... International Immunopharmacology 90, 107226, 2021 | 8 | 2021 |
| Engineered antibodies to combat viral threats X Yu, MS Cragg Nature 588 (7838), 398-399, 2020 | 2 | 2020 |
| Immunoglobulin G Fc glycans are not essential for antibody-mediated immune suppression to murine erythrocytes D Marjoram, Y Cruz-Leal, L Bernardo, NPL Le, M Crispin, X Yu, ... Blood, The Journal of the American Society of Hematology 130 (26), 2902-2905, 2017 | 2 | 2017 |
